Key result
The Myval Octacor transcatheter heart valve demonstrated a median regurgitation fraction of 2%, with moderate or greater residual aortic regurgitation occurring in 1.9% of patients.
Why the study?
The newly designed Myval Octacor THV was introduced to reduce aortic regurgitation, but its performance needed evaluation using quantitative videodensitometry angiography in first-in-human use.
Does the Myval Octacor THV system result in low rates of residual aortic regurgitation in patients undergoing transcatheter heart valve implantation?
Observational (n=125)
Yes
Does the Myval Octacor THV system result in low rates of residual aortic regurgitation in patients undergoing transcatheter heart valve implantation?
The first-in-human use of the Myval Octacor THV system demonstrated low rates of moderate or greater residual aortic regurgitation (1.9%) by quantitative angiography.
Hypothesis-generating for Myval Octacor in minimizing AR; leaves open randomized confirmation before practice change.
BACKGROUND: The balloon expandable Myval transcatheter heart valve (THV) showed encouraging results regarding residual aortic regurgitation (AR) from multiple observational studies. The newly designed Myval Octacor has been introduced recently, aiming for a reduction in AR and improved performance. OBJECTIVES: The focus of this study is to report the incidence of AR using the validated quantitative Videodensitometry angiography technology (qLVOT-AR%) in the first in human use of the Myval Octacor THV system. METHODOLOGY: We report on the first in human use of the Myval Octacor THV system in 125 patients in 18 Indian centres. Independent retrospective analysis of the final aortograms following implantation of the Myval Octacor was performed using the CAAS-A-Valve software. AR is reported as a regurgitation fraction. The previously validated cutoff values have been used to identify ≥moderate AR (RF% >17%), mild (6% < RF% ≤17%), and none or trace AR (RF% ≤ 6%). RESULTS: Final aortogram was analysable for 103 patients (84.4%) among the 122 available aortograms. 64 (62%) patients, had tricuspid aortic valve (TAV), 38 (37%) with bicuspid AV (BAV), and one with unicuspid AV. The median absolute RF% was 2% [1, 6], moderate or more AR incidence was 1.9%, mild AR in 20.4%, and none or trace AR in 77.7%. The two cases with RF% >17% were in the BAV group. CONCLUSION: The initial results of Myval Octacor using quantitative angiography-derived regurgitation fraction demonstrated a favourable outcome regarding residual AR, possibly due to improved device design. Results must be confirmed in a larger randomised study, including other imaging modalities.
No takes yet. Share an insight, caveat, or question.
Elkoumy et al. (2023) conducted an observational in Aortic regurgitation (n=125). Myval Octacor THV system was evaluated on Incidence of aortic regurgitation using quantitative Videodensitometry angiography technology (qLVOT-AR%). The Myval Octacor transcatheter heart valve demonstrated a median regurgitation fraction of 2%, with moderate or greater residual aortic regurgitation occurring in 1.9% of patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: